Table 3.
HRb for U | Prevalence (%) of U in Matched Thrice-Weekly In-Center Hemodialysis Patients | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
100 | 90 | 80 | 70 | 60 | 50 | 40 | 30 | 20 | 10 | 0 | |
0.90 | 0.87 | 0.88 | 0.89 | 0.90 | 0.91 | 0.92 | 0.93 | 0.94 | 0.95 | 0.96 | 0.97 |
0.80 | 0.87 | 0.89 | 0.91 | 0.94 | 0.96 | 0.98 | 1.00 | 1.02 | 1.04 | 1.07 | 1.09 |
0.70 | 0.87 | 0.91 | 0.94 | 0.98 | 1.02 | 1.06 | 1.09 | 1.13 | 1.17 | 1.21 | 1.24 |
0.60 | 0.87 | 0.93 | 0.99 | 1.04 | 1.10 | 1.16 | 1.22 | 1.28 | 1.33 | 1.39 | 1.45 |
0.50 | 0.87 | 0.96 | 1.04 | 1.13 | 1.22 | 1.31 | 1.39 | 1.48 | 1.57 | 1.65 | 1.74 |
Referent: matched thrice-weekly in-center hemodialysis patients.
The prevalence of U was assumed to be 100% in daily home hemodialysis patients.
The independent effect of U (e.g., yes versus no) on risk of death.